Selection of publications

Korstanje C, Mathy M-J, Van Charldorp K, De Jonge A, Van Zwieten PA. Influence of respiratory acidosis or alkalosis on pressor responses mediated by α1– and α2– adrenoceptors in pithed normotensive rats. Naunyn-Schmiedeberg’s Arch Pharmacol 330:187-192,1985.

Korstanje C, Jonkman FAM, Van Kemenade JE, Van Zwieten PA. Bay k-8644, a calcium entry promoter, as antidote in verapamil intoxication in rabbits. Arch int Pharmacodyn Ther 287:109-119,1987.

Knoppert NW, Nijmeijer SM, Van Duin CTM, Korstanje C, Van Gogh H, Van Miert, ASJPAM. Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats. J Vet Pharmacol Therap 11:135-144,1988.

Witkamp RF, Korstanje C, Van Miert ASJPAM. Toxicological and pharmacological effects of the use of somatotropin in dairy farming. Tijdschr Diergeneeskd 115:780-788,1990.

Korstanje C, Ligtvoet FPT, Van Hemert KMF. Differential effects of dermatological cream bases with respect to skin surface moisturizing capacity: a study design in volunteers. J Dermatol Treatment 2137-139,1992.

De Jong EMGJ, Ferrier CM, De Zwart A, Wauben-Penris PJJ, Korstanje C, Van de Kerkhof PCM. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 9:185-194,1995.

Martin SW, Radley SC, Chess-Williams R, Korstanje C, Chapple CR. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 80:405-413,1997.

Korstanje C. Dose-response approach in clinical testing of antigen-specific immunotherapies. In: Specific Immunotherapy of chronic autoimmune diseases, Van Eden W, De Boer M, Bijlsma JWJ, De Vries RPP, Melief CJM, Ed. Royal Netherlands Academy of Arts and Sciences, Amsterdam, pp 133-134,1999.

Korstanje C. Barnidipine, a long-acting slow onset calcium antagonist. Int J Clin Pract 114,Suppl:2-6,2000.

Wegener JW, Korstanje C, Nawrath H. Differential effects of dihydropyridines on tension and L-type calcium channel currents in vascular smooth muscle preparations from the rat. J Hypertens 19(Suppl 2):S300,2001.

Carballido J, Prieto A, Sanz M, Navarrete RV, Korstanje C, Alvarez de Mon M. Tamsulosin modulates the pattern of growth factors in epithelial prostate cells from benign hyperplasia in patients. BJU Intl Suppl 2002.

Sellers DJ, Hill C, White S, Chess-Williams R, Korstanje C, Chapple CR. Investigation of the selectivity of solifenacin in rat bladder vs salivary gland. J Urol 169(Suppl 4):40,2003.

Korstanje C. Editorial overview: Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development. Curr Opin Invest Drugs 4:519-521,2003.

Korstanje C. The improved cardiovascular safety of Omnic (tamsulosin) oral controlled absorption system (OCAS™). Eur Urol Suppl 4:10-13,2005.

Korstanje C. β3-Adrenoceptor (β3-AR) agonists in control of overactive bladder (OAB) function – translational aspects. Presentation at WorldPharma2010 Workshop on Adrenoceptors, 18 July 2010.

Korstanje C, Krauwinkel W, van Doesum-Wolters FL. Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity? Br J Clin Pharmacol 72:218-225,2011.

Gillespie JI, Palea S, Guilloteau V, Guerard M, Llluel P, Korstanje C. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 110:E132-142,2012.

Van Koeveringe G, Rademakers KLJ, Korstanje C, Daneshgari F, Ruggieri MR, Igawa Y, Fry C, Wagg A. Detrusor underactivity: Pathophysiological considerations, models and proposals for future research. ICI-RS 2013. Neurourol Urodyn 33:591-596,2014.

Eastham J, Stephenson C, Korstanje C, Gillespie JI. The expression of β3-adrenoceptor and muscarinic type 3 receptor immune-reactivity in the major pelvic ganglion of the rat. Naunyn-Schmiedeberg’s Arch Pharmacol 388:695-708,2015.

Michel MC, Korstanje C. β3-Adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a re-positioning clinical drug development project. Pharmacology & Therapeutics 159:66-82,2016.

Van Gelderen M, Stolzel M, Meijer J, Kerbusch V, Collins C, Korstanje C. An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects. J Clin Pharmacol 57:1534-1544,2017.

Korstanje C, Suzuki M, Yuno K, Sato S, Ukai M, Schneidkraut MJ, Yan GX. Translational science approach for assessment of cardiovacular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. J Pharmacol Toxicol Methods 87,74-81,2017.